Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

Bone

Volumn 42, Issue 4, 2008, Pages 669-680

  Qiang, Ya Wei ^a   Barlogie, Bart ^a   Rudikoff, Stuart ^b   Shaughnessy Jr , John D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BMP 2; Bone disease; Dkk1; Myeloma; Osteoblast; Wnt

Indexed keywords

ALKALINE PHOSPHATASE; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; DKK1 PROTEIN; FRIZZLED PROTEIN; GLUTATHIONE TRANSFERASE; MESSENGER RNA; PROTEIN DERIVATIVE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN; WNT3 PROTEIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; CYTOPLASM; ENZYME ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; ANIMALS; BETA CATENIN; BONE DISEASES, METABOLIC; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LDL-RECEPTOR RELATED PROTEINS; MICE; MULTIPLE MYELOMA; OSTEOBLASTS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEINS;

EID: 40849083276     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.12.006     Document Type: Article

References (54)

1. Pearse R.N., Sordillo E.M., Yaccoby S., Wong B.R., Liau D.F., Colman N., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98 20 (2001) 11581-11586
2. Sezer O., Heider U., Zavrski I., Kuhne C.A., and Hofbauer L.C. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101 6 (2003) 2094-2098
3. Berenson J.R. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin Oncol 28 2 Suppl 6 (2001) 25-34
4. Bataille R., Chappard D., Marcelli C., Dessauw P., Sany J., Baldet P., et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7 12 (1989) 1909-1914
5. Taube T., Beneton M.N., McCloskey E.V., Rogers S., Greaves M., and Kanis J.A. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49 4 (1992) 192-198
6. Hashimoto T., Abe M., Oshima T., Shibata H., Ozaki S., Inoue D., et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 125 1 (2004) 38-41
7. Nusse R. Wnt signaling in disease and in development. Cell Res 15 1 (2005) 28-32
8. Westendorf J.J., Kahler R.A., and Schroeder T.M. Wnt signaling in osteoblasts and bone diseases. Gene 341 (2004) 19-39
9. Qiang Y., and Rudikoff S. Wnt signaling in B and T lymphocytes. Front Biosci 9 (2004) 1000-1010
10. Qiang Y., Walsh K., Yao L., Kedei N., Blumberg P., Rubin J., et al. Wnts induce migration and invasion of myeloma plasma cells. Blood 106 (2005) 1786-1793
11. He X., Semenov M., Tamai K., and Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 131 8 (2004) 1663-1677
12. Nelson W.J., and Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303 5663 (2004) 1483-1487
13. Holmen S.L., Zylstra C.R., Mukherjee A., Sigler R.E., Faugere M.C., Bouxsein M.L., et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280 22 (2005) 21162-21168
14. Stewart J.P., and Shaughnessy Jr. J.D. Role of osteoblast suppression in multiple myeloma. J Cell Biochem 98 1 (2006) 1-13
15. Bradbury J.M., Niemeyer C.C., Dale T.C., and Edwards P.A. Alterations of the growth characteristics of the fibroblast cell line C3H 10T1/2 by members of the Wnt gene family. Oncogene 9 9 (1994) 2597-2603
16. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 4 (2001) 513-523
17. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346 20 (2002) 1513-1521
18. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70 1 (2002) 11-19
19. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass II D.A., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157 2 (2002) 303-314
20. Bennett C.N., Longo K.A., Wright W.S., Suva L.J., Lane T.F., Hankenson K.D., et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 102 9 (2005) 3324-3329
21. Hu H., Hilton M.J., Tu X., Yu K., Ornitz D.M., and Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132 1 (2005) 49-60
22. Rawadi G., Vayssiere B., Dunn F., Baron R., and Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18 10 (2003) 1842-1853
23. Kawano Y., and Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116 Pt 13 (2003) 2627-2634
24. Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A., and Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411 (2001) 321-325
25. Mao B., Wu W., Davidson G., Marhold J., Li M., Mechler B.M., et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417 6889 (2002) 664-667
26. Li J., Sarosi I., Cattley R.C., Pretorius J., Asuncion F., Grisanti M., et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39 4 (2006) 754-766
27. Morvan F., Boulukos K., Clement-Lacroix P., Roman Roman S., Suc-Royer I., Vayssiere B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21 6 (2006) 934-945
28. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 26 (2003) 2483-2494
29. Hall C.L., Bafico A., Dai J., Aaronson S.A., and Keller E.T. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65 17 (2005) 7554-7560
30. Chung E.J., Hwang S.G., Nguyen P., Lee S., Kim J.S., Kim J.W., et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 100 3 (2002) 982-990
31. Qiang Y., Endo Y., Rubin J., and Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene 22 (2003) 1536-1545
32. Qiang Y., Kopantzev E., and Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99 (2002) 4138-4146
33. Bafico A., Gazit A., Wu-Morgan S.S., Yaniv A., and Aaronson S.A. Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts. Oncogene 16 21 (1998) 2819-2825
34. -/- colon carcinoma. Science 275 5307 (1997) 1784-1787
35. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 4 (2001) 402-408
36. Cheng S.L., Lecanda F., Davidson M.K., Warlow P.M., Zhang S.F., Zhang L., et al. Human osteoblasts express a repertoire of cadherins, which are critical for BMP-2-induced osteogenic differentiation. J Bone Miner Res 13 4 (1998) 633-644
37. van Noort M., Meeldijk J., van der Zee R., Destree O., and Clevers H. Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem 277 20 (2002) 17901-17905
38. Nishimura R., Kato Y., Chen D., Harris S.E., Mundy G.R., and Yoneda T. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem 273 4 (1998) 1872-1879
39. Itoh F., Asao H., Sugamura K., Heldin C.H., ten Dijke P., and Itoh S. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J 20 15 (2001) 4132-4142
40. Wang Q., Wei X., Zhu T., Zhang M., Shen R., Xing L., et al. Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2. J Biol Chem 282 14 (2007) 10742-10748
41. Giuliani N., Rizzoli V., and Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108 (2006) 3992-3996
42. Oshima T., Abe M., Asano J., Hara T., Kitazoe K., Sekimoto E., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106 9 (2005) 3160-3165
43. Li X., Liu P., Liu W., Maye P., Zhang J., Zhang Y., et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 37 9 (2005) 945-952
44. van der Horst G., van der Werf S.M., Farih-Sips H., van Bezooijen R.L., Lowik C.W., and Karperien M. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. J Bone Miner Res 20 10 (2005) 1867-1877
45. Kokubu C., Heinzmann U., Kokubu T., Sakai N., Kubota T., Kawai M., et al. Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development 131 21 (2004) 5469-5480
46. Glass II D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8 5 (2005) 751-764
47. Canalis E., Economides A.N., and Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24 2 (2003) 218-235
48. Chen Y., Whetstone H.C., Youn A., Nadesan P., Chow E.C., Lin A.C., et al. Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J Biol Chem 282 (2006) 526-533
49. Mbalaviele G., Sheikh S., Stains J.P., Salazar V.S., Cheng S.L., Chen D., et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem 94 2 (2005) 403-418
50. Nakashima A., Katagiri T., and Tamura M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J Biol Chem 280 45 (2005) 37660-37668
51. Hu M.C., and Rosenblum N.D. Smad1, beta-catenin and Tcf4 associate in a molecular complex with the Myc promoter in dysplastic renal tissue and cooperate to control Myc transcription. Development 132 1 (2005) 215-225
52. Willert J., Epping M., Pollack J.R., Brown P.O., and Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2 (2002) 8-15
53. Binato R., Alvarez Martinez C.E., Pizzatti L., Robert B., and Abdelhay E. SMAD 8 binding to mice Msx1 basal promoter is required for transcriptional activation. Biochem J 393 Pt 1 (2006) 141-150
54. Binnerts M.E., Kim K.A., Bright J.M., Patel S.M., Tran K., Zhou M., et al. R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci U S A 104 37 (2007) 14700-14705